Immunic Inc CEO Daniel Vitt speaks to Proactive's Stephen Gunnion about the rise of autoimmune diseases such as multiple sclerosis (MS) and celiac disease, attributing this trend to environmental and diagnostic factors. Vitt highlighted how better diagnostic tools have identified more cases, previously undetected. Vitt discussed Immunic’s lead asset for treating MS, emphasizing the urgent need for treatments addressing disability worsening, which current drugs do not fully cover. He explained the unique attributes of the oral small molecule vidofludimus calcium, developed by Immunic, which has a triple activity - anti-inflammatory, antiviral, and neuroprotective properties. This combination could address the unmet need in MS treatments, particularly in non-relapsing patients. Vitt also updated on the recruitment progress for Immunic's phase 3 trials in relapsing MS, stating the trials are on schedule. He expressed optimism about the potential of their phase 2 results in progressive MS expected in April 2025, describing it as a possible game-changer. Visit Proactive's YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for future content. #ImmunicInc #AutoimmuneDiseases #MultipleSclerosis #MSResearch #VidofludimusCalcium #Biotech #HealthcareInnovation #ClinicalTrials #Neuroprotection #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews